Memantina Flas Cinfa

Memantine, the active ingredient in Memantina Flas Cinfa, is a NMDA receptor antagonist presented as an oral formulation for oral use. It is employed in the management of Alzheimer’s disease to help preserve cognitive function in affected patients.

GNH USA supplies Memantina Flas Cinfa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantine is indicated for Alzheimer’s disease, acting on the glutamatergic pathway to mitigate neuronal excitotoxicity.

Alzheimer's disease (mild to moderate): improves cognition and daily functioning in patients with early‑stage disease. Alzheimer's disease (severe): helps maintain residual cognitive abilities and may reduce behavioral disturbances.

Memantine may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Dizziness: transient sensation of light‑headedness. - Headache: mild to moderate intensity. - Constipation: reduced bowel movements. - Confusion: temporary mental clouding. - Fatigue: feeling unusually tired. - Hypertension: elevated blood pressure readings.

Serious or Rare Side Effects: - Seizures: occurrence of convulsive episodes. - Allergic reactions: rash, itching, swelling. - Hallucinations: visual or auditory disturbances. - Cardiac arrhythmia: irregular heart rhythm. - Severe hypotension: sudden drop in blood pressure. - Liver enzyme elevation: abnormal hepatic function tests.

Before initiating therapy, consider the following safety measures. - Renal impairment: assess kidney function and adjust dose if necessary. - Hepatic impairment: monitor liver enzymes regularly. - History of seizures: observe for increased seizure activity. - Concurrent NMDA antagonists: avoid combined use to prevent additive toxicity. - Pregnancy: safety not established; use only if benefits outweigh risks. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Memantine can interact with several medications; awareness of interaction severity is essential.

Major Interactions (Avoid): - Amantadine: may increase neurotoxic risk. - Ketamine: additive NMDA antagonism can cause excessive CNS depression. - Methylphenidate: heightened neuropsychiatric adverse effects.

Moderate Interactions (Monitor Closely): - Anticholinergics: may worsen cognitive deficits. - CNS depressants (e.g., benzodiazepines): can enhance dizziness and sedation. - Diuretics: potential for electrolyte imbalance affecting drug levels.